Implementation of Stereotactic Accelerated Partial Breast Irradiation Using Cyber-Knife – Technical Considerations and Early Experiences of a Phase II Clinical Study

• Published in: Pathology oncology research Vol. 26; no. 4; pp. 2307 - 2313
• Main Authors: Mészáros, Norbert, Smanykó, Viktor, Major, Tibor, Stelczer, Gábor, Jánváry, Levente, Kovács, Eszter, Mária, Bahéri, Zaka, Zoltán, Pukancsik, Dávid, Takácsi-Nagy, Zoltán, Polgár, Csaba
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.10.2020; Springer Nature B.V
• Subjects: Arm; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer Research; Edema; Erythema; Immunology; Invasiveness; Mastectomy; Oncology; Original; Original Article; Pathology; Patients; Post-menopause; Radiation; Robotic surgery; Side effects; Surgery; APBI; Breast cancer; Phase II; Cyber-knife; SBRT
• ISSN: 1219-4956; 1532-2807
• DOI: 10.1007/s12253-020-00821-3

To report the implementation, dosimetric results of and early experiences with stereotactic accelerated partial breast irradiation (SAPBI) following breast conserving surgery (BCS) for postmenopausal low-risk St I-II invasive breast cancer (IBC) patients. Between November 2018 and August 2019, 27 patients were registered in our phase II prospective study. SAPBI was performed with Cyber-Knife (CK) M6 machine, in 4 daily fractions of 6.25 Gy to a total dose of 25 Gy. Respiratory movements were followed with implanted gold markers and Synchrony system. Corrections for patient displacement and respiratory movement during treatment were performed with the robotic arm. Early side effects, cosmetic results, and dosimetric parameters were assessed. The average volume of the surgical cavity, clinical target volume (CTV), and planning target volume (PTV_EVAL) were 8.1 cm 3 (range: 1.75–27.3 cm 3 ), 55.3 cm 3 (range: 26.2–103.5 cm 3 ), and 75.7 cm 3 (range: 40–135.4 cm 3 ), respectively. The mean value of the PTV_eval/whole breast volume ratio was 0.09 (range: 0.04–0.19). No grade 2 or worst acute side-effect was detected. Grade 1 (G1) erythema occurred in 6 (22.2%) patients, while G1 oedema was reported by 3 (11.1%) cases. G1 pain was observed in 1 (3.4%) patient. Cosmetic result were excellent in 17 (62.9%) and good in 10 (37.1%) patients. SAPBI with CK is a suitable and practicable technique for the delivery of APBI after BCS for low-risk, St. I-II. IBC. Our early findings are encouraging, CK-SAPBI performed with four daily fractions is convenient and perfectly tolerated by the patients.